Excellent performance by new drugs at AstraZeneca led to 18% growth in the group’s sales, while the core operating profit grew by 8%, both outperforming the street as well as our expectations. Oncology continued to be at the forefront of this growth, supported by CVRM and respiratory. Top-line guidance for the year was upped, while core EPS guidance was maintained.

26 Jul 2019
The 2Cs - Cancer and China – underpin the guidance upgrade

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The 2Cs - Cancer and China – underpin the guidance upgrade
AstraZeneca PLC (AZN:LON) | 10,632 19350.2 1.7% | Mkt Cap: 164,867m
- Published:
26 Jul 2019 -
Author:
Kamla Singh -
Pages:
3 -
Excellent performance by new drugs at AstraZeneca led to 18% growth in the group’s sales, while the core operating profit grew by 8%, both outperforming the street as well as our expectations. Oncology continued to be at the forefront of this growth, supported by CVRM and respiratory. Top-line guidance for the year was upped, while core EPS guidance was maintained.